Anonymized samples were representative of the US blood donor population ( n = 5000 ) , healthy UK donors ( n = 200 ) , patients with nonprion neurodegenerative diseases ( n = 352 ) , patients in whom a prion disease diagnosis was likely ( n = 105 ) , and patients with confirmed vCJD ( n = 10 ) .